Verdict94/ 100
Grade A · #1CoreAge Rx
The most honest middle of the market: nationwide access, both molecules at one flat, no-surprise price.
Visit CoreAge RxHead-to-head verdict
CoreAge Rx vs Somi Health
Two GLP-1 providers, compared side by side on The Verdict Score — our published six-factor rubric. Same yardstick, and no score is adjusted for payment.
Published by The GLP-1 Verdict
Pricing sources checked: CoreAge Rx: August 2026 · Somi Health: Check date not recorded
vs
Verdict69/ 100
Grade C · #202Somi Health
Somi Health is a telehealth weight-loss provider offering compounded GLP-1 medications - compounded semaglutide and tirzepatide injections plus an oral semaglutide tablet.
Visit Somi HealthThe verdict
Winner: CoreAge Rx
CoreAge Rx takes it with a higher Verdict Score — 94/100 to 69/100 (grade A vs C). Anyone who wants transparent flat pricing and nationwide access without a teaser-rate bait-and-switch. Somi Health still earns its place — low-cost compounded semaglutide or tirzepatide, plus an oral no-needle option.
The score compares published program terms and features; it does not measure clinical outcomes or predict which treatment will suit you.
Factor by factor
Both scored on the same six factors — see the methodology. The brass bar marks the stronger side on each.
92Real-world results75
92
Real-world results75
97Price honesty64
97
Price honesty64
96Prescriber access57
96
Prescriber access57
88Formulary choice88
88
Formulary choice88
95Cancellation fairness56
95
Cancellation fairness56
93Member support74
93
Member support74
Price, coverage & features
| Metric | CoreAge Rx | Somi Health |
|---|---|---|
| Verdict Score | 94/100 | 69/100 |
| Grade | A | C |
| Semaglutide | $99/mo | From $135/mo (starting dose, compounded) |
| Tirzepatide | $149/mo | From $165/mo (starting dose, compounded) |
| Coverage | All 50 states | Not disclosed |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | No | Yes |
CoreAge Rx
What we like
- Flat, all-in monthly price with no intro-rate step-ups after month one
- Both compounded semaglutide and tirzepatide on one account
- Available in all 50 states
- Straightforward, low-friction cancellation
The caveats
- Not the cheapest — flat-price challengers like Trimi Health and Alan Meds undercut its sticker price
- No FDA-approved brand-name option (compounded only)
- Does not yet publicly name its 503A/B pharmacy partner
Somi Health
What we like
- among the lowest we track compounded prices: semaglutide $135/mo, tirzepatide $165/mo (3-month plan)
- Oral semaglutide tablet option for those who want no injections
- One price at any dose, with the medical visit and shipping included
- LegitScript Approved seal displayed; partnered with 503A pharmacies
- Free 2-5 day shipping; no insurance required
The caveats
- Compounded only - no brand-name Wegovy, Zepbound, Ozempic or Mounjaro
- Homepage advertises a 100% money-back guarantee but Terms state all sales are final, no refunds on medication
- Partner pharmacies are not individually named (material transparency gap)
- No single prescribing medical group named; only affiliated professional entities
- State availability not published; confirmed only during intake
Our pick — visit
Anyone who wants transparent flat pricing and nationwide access without a teaser-rate bait-and-switch.
Visit CoreAge Rx Read the full CoreAge Rx review →Also worth a look
Low-cost compounded semaglutide or tirzepatide, plus an oral no-needle option.
Visit Somi Health Read the full Somi Health review →Keep comparing
Neither of these has to be the answer: the rivals we rank against CoreAge Rx cover the 7 programs closest to it, and the same shortlist for Somi Health does the reverse.
More on CoreAge Rx
More on Somi Health
Or browse the full comparison hub, every head-to-head A to Z and the complete rankings.
Pricing, states and verification reflect each provider's public disclosures at last review; the Verdict Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.